Wouter Haazen

908 citations
28 papers · 660 · h-index 14

Impact in

Papers in

  • Epidemiology 11
    • Respiratory viral infections research 5
    • Urinary Tract Infections Management 3
  • Infectious Diseases 10
    • Viral gastroenteritis research and epidemiology 4
    • HIV/AIDS Research and Interventions 3
Co-authors
Marina De Smet (3 shared papers)Stephen H. Norris (4 shared papers)Joachim Stangier (4 shared papers)Benjamin Lang (4 shared papers)Viktoria Moschetti (4 shared papers)Stephan Glund (4 shared papers)Paul Reilly (3 shared papers)Esther Heijnen (5 shared papers)
Journals
Open Forum Infectious Diseases (5 papers)The Journal of Infectious Diseases (3 papers)Journal of Hepatology (2 papers)Journal of Crohn s and Colitis (2 papers)The Journal of Clinical Pharmacology (2 papers)
Partner nations
United StatesBelgiumNetherlands

In The Last Decade

Wouter Haazen

28 papers receiving 634 citations

Peers

Wouter Haazen
Comparison fields: 5 of 76
  • Internal Medicine 75
  • Virology 65
  • Infectious Diseases 234
  • Microbiology 74
  • Endocrinology 56
Replace Fernando Ballester Laguna with:
Fernando Ballester Laguna Spain
Beth A. Dy United States
R Thorpe
A Terragna Italy
Daniel Bernstein United States
Novella Carannante Italy
C. Flateau France
Serena Vita Italy
Peyton Metzel United States
Christina Jorup-Rönström Sweden
Wouter Haazen relative to Fernando Ballester Laguna Spain Fernando Ballester Laguna's profile →
Citations per field
00.5×5×10×15×18.7×
Fernando Ballester Laguna · 1×
Citations per year

Countries citing papers authored by Wouter Haazen

Since Specialization
Citations

This map shows the geographic impact of Wouter Haazen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter Haazen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter Haazen more than expected).

Fields of papers citing papers by Wouter Haazen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter Haazen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter Haazen. The network helps show where Wouter Haazen may publish in the future.

Co-authors

The 25 scholars most cited alongside Wouter Haazen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wouter Haazen Line = papers co-authored together Wouter Haazen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
The Journal of Infectious Diseases ·Jerald Sadoff, Els De Paepe, John P. DeVincenzo, Efi Gymnopoulou, Joris Menten, Bryan Murray, Arangassery Rosemary Bastian, An Vandebosch, Wouter Haazen, Nicolas Noulin, Christy Comeaux, Esther Heijnen, Kingsley Eze, Anthony Gilbert, Rob Lambkin‐Williams, Hanneke Schuitemaker, Benoît Callendret
202167
2
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
AIDS ·Annaléne Nel, Wouter Haazen, Jeremy Nuttall, Joseph Romano, Zeda Rosenberg, Neliëtte van Niekerk
201460
3
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects
Blood ·Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly
201459
4
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
Clinical Pharmacokinetics ·Stephan Glund, Joachim Stangier, Joanne van Ryn, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly, Jörg Kreuzer
201658
5
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial
The Lancet Infectious Diseases ·Robert W. Frenck, John Ervin, Laurence Chu, Darren Abbanat, Bart Spiessens, Oscar Go, Wouter Haazen, Germie van den Dobbelsteen, Jan Poolman, S Thoelen, Patricia Palacios
201957
6
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Antimicrobial Agents and Chemotherapy ·Marian Iwamoto, Larissa Wenning, Amelia S. Petry, Martine E. Laethem, Marina De Smet, James Kost, Sheila Breidinger, Eric Mangin, Neal Azrolan, Howard Greenberg, Wouter Haazen, Julie A. Stone, Keith Gottesdiener, John A. Wagner
200853
7
Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects
The Journal of Clinical Pharmacology ·Goutam C. Mistry, Arthur Bergman, Wen‐Lin Luo, Caroline Cilissen, Wouter Haazen, Michael J. Davies, Keith Gottesdiener, John A. Wagner, Gary Herman
200742
8
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
The Journal of Infectious Diseases ·Jerald Sadoff, Els De Paepe, Wouter Haazen, Edmund Omoruyi, Arangassery Rosemary Bastian, Christy Comeaux, Esther Heijnen, Cynthia Strout, Hanneke Schuitemaker, Benoît Callendret
202042
9
A human anti‐D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti‐D antibodies
British Journal of Haematology ·R Béliard, Tony Waegemans, Dominique Notelet, Léna Massad, F. Dhainaut, Christophe de Romeuf, Eric Guémas, Wouter Haazen, Dominique Bourel, Jean‐Luc Teillaud, Jean‐François Prost
200830
10
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
The Journal of Clinical Pharmacology ·Rajesh Krishna, Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias Noel Gendrano, Martine Robberechts, Wouter Haazen, Jan de Hoon, Marleen Depré, Ashley Martucci, Joanna Peng, Amy O. Johnson‐Levonas, John A. Wagner, S. Aubrey Stoch
201629
11
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
The Journal of Infectious Diseases ·Arabella Stuart, Miia Virta, Kristi L. Williams, Ilkka Seppä, Robyn Hartvickson, Melanie Greenland, Edmund Omoruyi, Arangassery Rosemary Bastian, Wouter Haazen, Nadine C. Salisch, Efi Gymnopoulou, Benoît Callendret, Saul N. Faust, Matthew D. Snape, Esther Heijnen
202228
12
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults
Vaccine ·Geert Leroux‐Roels, Pierre Van Damme, Wouter Haazen, Sepehr Shakib, Magalie Caubet, Emmanuel Aris, Jeanne‐Marie Devaster, Mathieu Peeters
201627
13
Pharmacokinetics and Safety Assessment of Anti-HIV Dapivirine Vaginal Microbicide Rings with Multiple Dosing
Journal of AIDS & Clinical Research ·Wouter Haazen
201419
14
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study
Open Forum Infectious Diseases ·Carlos Fierro, Michal Sarnecki, Joachim Doua, Bart Spiessens, Oscar Go, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
202317
15
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
British Journal of Clinical Pharmacology ·Stephen H. Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Viktoria Moschetti, Susumu Imazu, Paul Reilly, Benjamin Lang, Joachim Stangier, Stephan Glund
20179
16
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI
npj Vaccines ·Carlos Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Tracey Day, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
20248
17
Drug-drug Interactions between the Dapivirine Vaginal Ring (Ring-004) and Miconazole Nitrate Vaginal Capsule (Gyno-Daktarin ® )
AIDS Research and Human Retroviruses ·Annaléne Nel, Wouter Haazen, Marisa Russell, Jeremy Nuttall, Neliëtte van Niekerk, Nicoline Treijtel
20148
18
2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS
Journal of Hepatology ·V. Detishin, Wouter Haazen, H. Robison, L. Robarge, Elizabeth Olek
20108
19
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
Open Forum Infectious Diseases ·John P. DeVincenzo, Efi Gymnopoulou, Els De Paepe, Bryan Murray, Arangassery Rosemary Bastian, Wouter Haazen, Nicolas Noulin, Christy Comeaux, Esther Heijnen, Kinglsey Eze, Anthony Gilbert, Rob Lambkin‐Williams, Hanneke Schuitemaker, Benoît Callendret, Jerald Sadoff
20198
20
Epidemiology and O-Serotypes of Extraintestinal Pathogenic Escherichia coli Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study
The Journal of Urology ·Steven Rosenberg, Marc J. M. Bonten, Wouter Haazen, Bart Spiessens, Darren Abbanat, Oscar Go, Florian Wagenlehner, Neal D. Shore, Yosuke Hagiwara, Patricia Palacios, Jeroen Geurtsen, Peter W. M. Hermans, Jan Poolman
20207

About Wouter Haazen

Wouter Haazen is a scholar working on Epidemiology, Infectious Diseases, Endocrinology, Molecular Biology and Cardiology and Cardiovascular Medicine, having authored 28 papers that have together received 660 indexed citations. Recurring topics across this work include Escherichia coli research studies (6 papers), Respiratory viral infections research (5 papers), Viral gastroenteritis research and epidemiology (4 papers), HIV Research and Treatment (3 papers), HIV/AIDS Research and Interventions (3 papers), Atrial Fibrillation Management and Outcomes (3 papers), Antibiotic Resistance in Bacteria (3 papers) and Urinary Tract Infections Management (3 papers). The work is most often cited by research in Internal Medicine (75 citations), Virology (65 citations), Infectious Diseases (234 citations), Microbiology (74 citations) and Endocrinology (56 citations). Wouter Haazen has collaborated with scholars based in United States, Belgium and Netherlands. Frequent co-authors include Marina De Smet, Stephen H. Norris, Joachim Stangier, Benjamin Lang, Viktoria Moschetti, Stephan Glund, Paul Reilly, Esther Heijnen, Dietmar Ganßer and Jeremy Nuttall. Their work appears in journals such as Open Forum Infectious Diseases, The Journal of Infectious Diseases, Journal of Hepatology, Journal of Crohn s and Colitis and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Ballester LagunaBreakdown of academic impact, for papers by Beth A. DyBreakdown of academic impact, for papers by R ThorpeBreakdown of academic impact, for papers by A TerragnaBreakdown of academic impact, for papers by Daniel BernsteinBreakdown of academic impact, for papers by Novella CarannanteBreakdown of academic impact, for papers by C. FlateauBreakdown of academic impact, for papers by Serena VitaBreakdown of academic impact, for papers by Peyton MetzelBreakdown of academic impact, for papers by Christina Jorup-Rönström